MBX Biosciences Inc - MBX STOCK NEWS

MBX Biosciences (Nasdaq: MBX) has appointed Steve Hoerter as an independent director to its Board of Directors. Hoerter brings over 30 years of pharmaceutical commercialization and executive leadership experience to the clinical-stage biopharmaceutical company.

Most recently, Hoerter served as President, CEO and Director of Deciphera Pharmaceuticals until its $2.4 billion acquisition by Ono Pharmaceutical in 2024. His previous roles include senior commercial leadership positions at Agios Pharmaceuticals, Clovis Oncology, Roche, and Genentech.

The appointment aims to support MBX's advancement of its pipeline focused on endocrine and metabolic disorders, including programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company leverages its Precision Endocrine Peptides™ technology platform.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's President and CEO, Kent Hawryluk, will deliver a podium presentation on Monday, April 7, 2025, from 8:00 a.m. to 8:40 a.m. ET. The presentation will be accompanied by one-on-one meetings.

Investors can access the live webcast through the investors section of MBX Biosciences' website at investors.mbxbio.com/news-events/events. A replay will be available approximately two hours after the event and will remain accessible for about 90 days on the company's website.

MBX Biosciences (Nasdaq: MBX) has announced its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company completed enrollment of 64 patients in its Phase 2 Avail™ trial of canvuparatide for hypoparathyroidism, with topline results expected in Q3 2025.

Key developments include positive Phase 1 results for MBX 1416 in post-bariatric hypoglycemia, with Phase 2 trials planned for 2H 2025. The company is also preparing an IND submission for MBX 4291, their obesity treatment candidate, in Q2 2025.

Financial highlights:

• Cash position: $262.1M as of December 31, 2024
• R&D expenses: $57.4M for 2024 (up from $28.5M in 2023)
• G&A expenses: $10.8M for 2024 (up from $6.8M in 2023)
• Net loss: $61.9M for 2024 (increased from $32.6M in 2023)

MBX Biosciences (Nasdaq: MBX) has strengthened its leadership team with two key appointments. Chatan Charan, Ph.D. joins as Senior Vice President of Pharmaceutical Development and CMC, bringing over 30 years of drug development experience, including his recent role at Harpoon Therapeutics where he contributed to its sale to Merck Pharmaceuticals.

Mark Hope has been appointed Senior Vice President of Regulatory and Quality, with three decades of regulatory expertise. He previously served at Cerevel Therapeutics, supporting its acquisition by AbbVie Inc. Both executives will support MBX's development of precision peptide therapies for endocrine and metabolic disorders.

MBX Biosciences (Nasdaq: MBX) has completed enrollment for its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), surpassing the initial target of 48 patients with 64 enrollees. The trial evaluates a long-acting parathyroid hormone peptide prodrug for treating chronic hypoparathyroidism (HP).

The study is a randomized, multicenter, 12-week, double-blind, placebo-controlled trial assessing safety, pharmacokinetics, and efficacy. The primary endpoint focuses on patients' ability to discontinue active vitamin D and reduce calcium supplements while maintaining normal serum albumin-adjusted calcium levels. Secondary endpoints include safety, tolerability, pharmacodynamic activity, and quality of life measures.

Topline results are expected in Q3 2025. The company believes canvuparatide could transform HP treatment by providing more consistent therapeutic effects and improved patient convenience.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in March 2025.

The company's President and CEO, Kent Hawryluk, will deliver a podium presentation at the TD Cowen 45th Annual Healthcare Conference in Boston on March 3, 2025, from 10:30-11:00 a.m. ET, along with one-on-one meetings. Additionally, MBX will participate in the Jefferies Biotech on the Beach Summit in Miami Beach on March 12th, featuring one-on-one meetings.

Webcasts of the presentations will be available on the investors section of MBX Biosciences' website, with replay access available approximately two hours post-event and archived for roughly 90 days.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in February 2025.

The company's President and CEO, Kent Hawryluk, will participate in:

• A fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025 (2:00-2:25 p.m. EST) in New York
• A panel presentation at the BIO CEO & Investor Conference on February 10, 2025 (11:00 a.m.-12:00 p.m. EST) in New York
• A podium presentation at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 (8:40-9:10 a.m. EST)

Live webcasts will be available on the MBX Biosciences investor website, with replay access available for approximately 90 days after each event.

MBX Biosciences (Nasdaq: MBX) announced positive Phase 1 results for MBX 1416, their investigational long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) treatment. The trial, involving 69 healthy volunteers, demonstrated that MBX 1416 was generally well-tolerated with a favorable safety profile.

Key findings include:

• No dose-related serious adverse events observed
• 90-hour median half-life supporting once-weekly dosing
• Dose-proportional concentration increases in both single and multiple ascending dose cohorts
• Increased GLP-1 levels within 60 minutes of meal tests

The company plans to initiate Phase 2 studies in PBH patients in the second half of 2025, pending FDA alignment at a mid-2025 End-of-Phase 1 meeting.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Kent Hawryluk, President and CEO, will deliver a presentation on January 14th, 2025, at 2:15 p.m. Pacific Time.

The company will engage in one-on-one investor meetings during the conference. A live webcast will be available through the investors section of MBX Biosciences' website, with replay access provided approximately two hours after the event and remaining accessible for about 30 days.